The Maharashtra Food and Drug Administration (FDA) has made substantial improvements to its testing facilities to address the continued high demand for drug regulation and quality testing. The FDA’s laboratories in Mumbai and Aurangabad have...
The plan by healthcare giant Manipal Hospitals to buy Pune-based Sahyadri Hospitals from international investor Ontario Teachers' Pension Plan Board in a deal valued at around Rs. 6,400 crore has been approved by the Competition Commission of India
Future presentations at the Ophthalmology Futures Retina Forum, the EURETINA Innovation Spotlight (EIS), the 25th European Society of Retina Specialists (EURETINA) Congress, and the Retina Society Annual Congress have been announced by
A UK-wide Commercial Research Delivery Centre (CRDC) Network will be established thanks to a £6.5 million investment from the National Institute for Health and Care Research (NIHR), which was made possible by public-private cooperation
The National Medical Products Administration (NMPA) of China has authorized Boehringer Ingelheim's Hernexeos (zongertinib tablets) as a monotherapy for the treatment of adult patients with non-small cell lung cancer (NSCLC) that is incurable, locally
India is planning to increase pharmaceutical exports to Russia, the Netherlands and Brazil, diversifying its markets beyond the United States, which remains its largest buyer. Two industry sources confirmed the move, highlighting tariff-related uncer
At the ESC Congress 2025 that took place in Madrid, Novo Nordisk presented findings from the STEER study, which indicated that Wegovy (semaglutide 2.4 mg) provides greater protection to cardiovascular risk than tirzepatide for people living with...
Glenmark Pharmaceuticals has announced its plans to launch Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials, in the United States this September. The product was determined to be bioequivalent and therapeutically equivalent...
Merck announced today positive topline data from its phase 3 CORALreef Lipids trial of enlicitide, an investigational oral PCSK9 inhibitor, in adults with hypercholesterolemia. The once-daily regimen achieved all primary and key secondary...
The BaxHTN phase III trial's full results were positive; patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo in addition to standard of care showed a statistically significant and clinically mean
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")